A new treatment for type 1 narcolepsy is now available in Japan and China.

Takeda Pharmaceutical (TAK) presented Phase 2/3 study results for TAK-881, showing a 42.6% reduction in infusion time for Primary Immunodeficiency Disease (PID) patients. The therapy met primary endpoints, demonstrating comparable efficacy and safety to HYQVIA. Takeda plans regulatory submissions in 2026. TAK stock is currently trading at $18.66, up 0.76%.

Takeda (TSE:4502/NYSE:TAK) announced positive Phase 2/3 trial results for TAK-881, an investigational treatment for Primary Immunodeficiency Disease (PID). The study met its primary endpoint, showing pharmacokinetic comparability to HYQVIA. TAK-881 demonstrated reduced infusion times and volume while maintaining safety and efficacy. Takeda plans regulatory submissions in 2026. The trial included 43 participants aged 16 and older, with comparable infection rates and safety profiles to HYQVIA.

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) presented Phase 2/3 trial results for TAK-881, showing it met primary endpoints. The drug demonstrated pharmacokinetic comparability to HYQVIA, with reduced infusion volume and time. Adverse events were mild to moderate, and regulatory filings are expected in fiscal 2026.

Takeda's zasocitinib showed superior efficacy over Bristol Myers Squibb's deucravacitinib in treating moderate to severe plaque psoriasis, with 36.5% of participants achieving complete clearance vs. 13.9%, according to a phase 3 study presented at the European Academy of Dermatology and Venerology Congress. Zasocitinib also demonstrated faster and more complete effects, with no new safety signals observed.

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

A phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.